Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity

A compound of Formula (VII):

• or a pharmaceutically acceptable salt thereof,
• wherein:
• R1 is hydrogen, CH3, C1-6 haloalkyl, O-phenyl, C3-8 carbocyclyl, or phenyl, wherein the CH3, C1-6 haloalkyl, O-phenyl, C3-8 carbocyclyl, or phenyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, ORc, and 3-8 membered heterocyclyl;
• each R2 is independently hydrogen, halo, or C1-6 alkyl;
• R3 is halo, cyano, nitro, C1-6 alkyl, C(O)Rc, C(O)N(Rd)2, C(O)ORc, N(Rd)2, OR7, C3-8 carbocyclyl, or 3-8 membered heterocyclyl, wherein the C1-6 alkyl, C3-8 carbocyclyl, or 3-8 membered heterocyclyl is optionally substituted with one or more independently selected R5 substituents;
• R4 is cyano, nitro, C1-6 alkyl, C(O)Rc, C(O)N(Rd)2, C(O)ORc, N(Rd)2, ORc, C3-8 carbocyclyl, or 3-8 membered heterocyclyl, wherein the C1-6 alkyl, C3-8 carbocyclyl, or 3-8 membered heterocyclyl is optionally substituted with one or more independently selected R5 substituents;
• each R5 is independently halo, cyano, nitro, C1-6 alkyl, C(O)N(Rd)2, N(Rd)2, NRdC(O)Rc, ORc, S(O)2Rc, S(O)2N(Rd)2, S(O)2ORc, C3-8 carbocyclyl, or 3-8 membered heterocyclyl;
• each Rc is independently hydrogen or C1-6 alkyl, wherein each C1-6 alkyl is optionally and independently substituted with one or more independently selected R6 substituents;
• each Rd is independently hydrogen or C1-6 alky];
• each R6 is independently halo, cyano, C3-8 carbocyclyl, or 3-8 membered heterocyclyl, wherein each C3-8 carbocyclyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of halo and cyano;
• R7 is C1-6 alkyl or C3-8 carbocyclyl, wherein the C1-6 alkyl or C3-8 carbocyclyl is optionally substituted with one or more independently selected R6 substituents;
• and
• m is 0, 1, or 2.